HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Polman, C H Articles by Killestein, J Search for Related Content PubMed PubMed Citation Articles by Polman, C H Articles by Killestein, J Topic Collections Relevant Article

Anti-myelin antibodies in multiple sclerosis: clinically useful?

Department of Neurology, Vrije Universiteit Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands

Correspondence to:
Correspondence to:
Dr Chris H Polman
Vrije Universiteit Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands;ch.polman@vumc.nl

Keywords: antibodies; biomarker; multiple sclerosis; myelin; prognostic marker

The first 150 words of the full text of this article appear below.

Despite numerous studies on prognostic disease markers in multiple sclerosis (MS), very few markers have emerged as clinically relevant. Often, early studies show great potential, but subsequent reports on the same marker yield inconsistent or even contradictory results. It is crucial to understand the reasons why various studies of the same marker lead to different conclusions.

Recently, Berger et al have reported a promising predictor of clinically definite MS in a cohort of patients with clinically isolated syndrome (CIS), positive findings on brain magnetic resonance imaging, and oligoclonal bands in their cerebrospinal fluid.¹ Of the 103 patients in their cohort, 64 (62%) were seropositive for either anti-myelin oligodendrocyte glycoprotein (MOG) or anti-myelin basic protein (MBP) or both IgM antibodies. Patients who were seropositive for both anti-MOG and anti-MBP (22%) had more frequent and earlier relapses than those who were seronegative. The presence of both antibodies predicted the conversion . . . [Full text of this article]

Relevant Article

Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event

S Rauer, B Euler, M Reindl, and T Berger
J. Neurol. Neurosurg. Psychiatry 2006 77: 739-742. [Abstract] [Full Text] [PDF]